Skip to content
  • info@inquismedical.com
  • 888-526-7738
  • 1530 O'Brien Drive, Suite A Menlo Park, CA 94025
Icon-linkedin-1
  • Home
  • Healthcare Providers
    • Technologies
    • Clinical Evidence
  • Patients & Caregivers
    • About VTE
    • FAQs
  • Company
    • About
    • Our Team
    • News & Articles
    • Careers
    • Contact
  • Home
  • Healthcare Providers
    • Technologies
    • Clinical Evidence
  • Patients & Caregivers
    • About VTE
    • FAQs
  • Company
    • About
    • Our Team
    • News & Articles
    • Careers
    • Contact
Contact Us
Uncategorized

Inquis Medical Announces $75 Million Series C Financing to Scale Commercial Adoption of its AVENTUS Thrombectomy System

Codflux LLC / January 12, 2026

Strategic investment follows a transformative year marked by the national launch of the AVENTUS thrombectomy system. MENLO PARK, Calif.–(BUSINESS WIRE)–Inquis […]

Uncategorized

Inquis Medical’s AVENTUS Thrombectomy System Receives FDA 510(k) Clearance for Treatment of Pulmonary Embolism

Codflux LLC / October 28, 2025

June 16, 2025 09:30 ET – Pioneering device combines precision clot removal with autologous blood reinfusion to address unmet needs

Uncategorized

Trial Finds Inquis Medical’s AVENTUS Thrombectomy System Safe and Effective for Patients with Pulmonary Embolism

Codflux LLC / October 28, 2025

May 02, 2025 11:50 ET – Results of AVENTUS IDE Trial presented at SCAI Scientific Sessions Inquis Medical, a leading

Uncategorized

Inquis Medical Completes Enrollment in U.S. Pivotal IDE Trial of the Aventus Thrombectomy System Designed to Treat Patients with Pulmonary Embolism

Codflux LLC / October 28, 2025

MENLO PARK, Calif. — January 13, 2025 – Inquis Medical, a leading innovator in venous thromboembolic disease treatment, today announced

Uncategorized

AVENTUS Thrombectomy System: Innovative Endovascular Solution for Pulmonary Embolism

Codflux LLC / October 28, 2025

November 26, 2024 –  A case example highlights the function of the AVENTUS System for the removal of emboli and

Uncategorized

Inquis Medical Announces $40 Million Series B Financing to Accelerate Advancement of Aventus Thrombectomy System Addressing Venus Thromboembolic Diseases

Codflux LLC / October 28, 2025

Nov 4, 2024 2:20 PM EST – MENLO PARK, Calif.–(BUSINESS WIRE)–Inquis Medical, a pioneering medical technology company specializing in advanced

Uncategorized

Unmet Needs in the PE Thrombectomy Space

Codflux LLC / October 28, 2025

July 9, 2024 –  With Steven Abramowitz, MD; Mehdi H. Shishehbor, DO, MPH, PhD; and Nora Tabori, MD What are

AVENTUS Simplifies PE.
Ultimate precision. Maximum efficiency. Optimal outcomes. 

Contact Us

Company

  • Home
  • Technologies
  • Clinical Evidence

About Inquis Medical

  • About
  • Our Team
  • Careers
  • Terms & Conditions

Contact Info

  • 888-526-7738
  • info@inquismedical.com
  • 1530 O'Brien Drive, Suite A, Menlo Park, CA 94025
Icon-linkedin X-twitter Youtube
Indications for Use: The AVENTUS Thrombectomy System is indicated for: The non-surgical removal of emboli and thrombi from blood vessels.Injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The AVENTUS Thrombectomy System is intended for use in the peripheral vasculature and for the treatment of pulmonary embolism.
Indications for Use: The AVENTUS Clot Management System is indicated for use with the AVENTUS Thrombectomy System for autologous blood transfusion.
©Copyright 2025 - Inquis Medical - All rights reserved
Design & Developed by Codflux LLC